CRL Charles River Laboratories International, Inc. logo

CRL Charles River Laboratories International, Inc.

Healthcare
$160.30+0.91%ClosedMarket Cap: $7.72B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

2.67

P/S

1.92

EV/EBITDA

13.16

DCF Value

$132.93

FCF Yield

5.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

31.9%

Operating Margin

11.8%

Net Margin

-4.6%

ROE

-5.7%

ROA

-2.4%

ROIC

7.1%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$995.8M$-14.8M$
Q4 null$994.2M$-276.6M$
FY null$4.02B$-144.3M$
Q3 null$1.00B$54.4M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$207.50

Target (Median)

$214.00

Target Range

$185.00 - $220.00

2 Strong Buy10 Buy5 Hold0 Sell1 Strong Sell
BarclaysOverweight
2026-05-08
Evercore ISI GroupOutperform
2026-05-08
JP MorganNeutral
2026-04-13
UBSNeutral
2026-02-25
TD CowenBuy
2026-02-20

Trading Activity

Insider Trades

View All
Andrews Nancy Cdirector
SellThu May 14
Thompson Craig B.director
SellTue May 12
Graves Paul Wdirector
SellTue May 12
Barg Stevendirector
SellTue May 12
WILSON VIRGINIA Mdirector
SellMon May 11

Company Info

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Country

US

Exchange

Beta

1.45

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Peers